Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyethyl starch 130/0.4 vs Ringer acetate in severe sepsis and septic shock
2009-010104-28Phase 3Completed
- Sponsor
- Rigshospitalet
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of hetastarch in sepsis and septic shock (2 arms), sponsored by Rigshospitalet. Primary endpoints: Composite of 90-day mortality or end-stage kidney disease, 90-day mortality and 1 more. Started Mar 2009; status: completed.
02
Drugs
hetastarch
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on 2009-010104-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010104-28.